Systemic antifungal agents: an update of established and new therapies (Q34605679)

3 August 2017

1 reference

title

Systemic antifungal agents: an update of established and new therapies (English)

1 reference

3 August 2017

Daniel S Loo

1

1 reference

3 August 2017

1 January 2006

1 reference

3 August 2017

Advances in dermatology

1 reference

3 August 2017

22

1 reference

3 August 2017

101-124

1 reference

Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Long-term efficacy of antifungals in toenail onychomycosis: a critical review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Long-term post-treatment follow-up of onychomycosis treated with terbinafine: a multicentre trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Successful treatment of toenail mycosis with terbinafine and itraconazole gives long term benefits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Relapses of onychomycosis after successful treatment with systemic antifungals: a three-year follow-up.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Nail incorporation kinetics of terbinafine in onychomycosis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Intermittent therapy with terbinafine for dermatophyte toe-onychomycosis: a new approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Pulse versus continuous terbinafine for onychomycosis: a randomized, double-blind, controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter canadian survey of 15,000 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Aetiology of onychomycosis in Al Ain, United Arab Emirates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Itraconazole pulse therapy for the treatment of Candida onychomycosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Efficacy and safety of terbinafine for nondermatophyte and mixed nondermatophyte and dermatophyte toenail onychomycosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Treatment of Candida nail infection with terbinafine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Onychomycosis in clinical practice: factors contributing to recurrence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

The evolving role of itraconazole, fluconazole and terbinafine in the treatment of tinea capitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Tinea capitis: a current perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

A randomized, double-blind, parallel-group, duration-finding study of oral terbinafine and open-label, high-dose griseofulvin in children with tinea capitis due to Microsporum species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Therapeutic options for the treatment of tinea capitis caused by Trichophyton species: griseofulvin versus the new oral antifungal agents, terbinafine, itraconazole, and fluconazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

A randomized controlled trial assessing the efficacy of fluconazole in the treatment of pediatric tinea capitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Terbinafine in the treatment of Trichophyton tinea capitis: a randomized, double-blind, parallel-group, duration-finding study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Efficacy and tolerability of 8 weeks' treatment with terbinafine in children with tinea capitis caused by Microsporum canis: a comparison of three doses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Treatment of Microsporum spp. tinea capitis with pulsed oral terbinafine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Itraconazole in the treatment of tinea capitis caused by Microsporum canis: experience in a large cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Fluconazole for the treatment of tinea capitis in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Intermittent short duration therapy with fluconazole is effective for tinea capitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Fluconazole in the treatment of tinea capitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Once weekly fluconazole is effective in children in the treatment of tinea capitis: a prospective, multicentre study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Epidemiology and treatment of tinea capitis: ketoconazole vs. griseofulvin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Itraconazole versus griseofulvin in the treatment of tinea capitis: a double-blind randomized study in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Voriconazole-a new therapeutic agent with an extended spectrum of antifungal activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

In vitro activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

In vitro activities of ravuconazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Cutaneous infection by Fusarium: successful treatment with oral voriconazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Madurella mycetomatis mycetoma treated successfully with oral voriconazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Two cases of subcutaneous Scedosporium apiospermum infection treated with voriconazole.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Scedosporium apiospermum soft tissue infection successfully treated with voriconazole: potential pitfalls in the transition from intravenous to oral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Case study: posaconazole treatment of disseminated phaeohyphomycosis due to Exophiala spinifera

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Comparison of caspofungin and amphotericin B for invasive candidiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2006.07.001

10.1016/J.YADR.2006.07.001

7 January 2021

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

17249298